Table 1.
Summary of patient’s clinical parameters
| Patient ID | FAB | % CD34+ | BM/PB | Expansion | Karyotype | FLT3-ITD | KIT mutation |
|---|---|---|---|---|---|---|---|
| 1 | M7 | 43 | PB | Yes | −7; +21 | − | − |
| 2 | M2 | 26 | PB | Yes | BCR-ABL, inv (16) | − | ND |
| 3 | M2 | 42 | BM | Yes | t(8;21) | − | + |
| 4 | M2 | 52 | PB | Yes | N | + | ND |
| 5 | M0 | 22 | PB | Yes | N | + | − |
| 6 | M5 | 88 | PB | Yes | N | − | ND |
| 7 | M1 | 70 | BM | Yes | +3q;−7;−10 | − | − |
| 8 | M0 | 70 | BM | Yes | 5q−;+6 | − | ND |
| 9 | M1 | 19 | PB | Yes | N | + | − |
| 10 | M1 | 19 | PB | Yes | N | ND | ND |
| 11 | M1 | 35 | BM | Yes | N | + | − |
| 12 | M5 | 14 | PB | Yes | t(11;20) | + | − |
| 13 | M1 | 57 | PB | Yes | N | − | − |
| 14 | M5 | 10 | BM | Yes | ND | − | ND |
| 15 | M5 | 0.5 | PB | Yes | N | + | ND |
| 16 | M1 | 63 | PB | No | 3p+; −7; +8 | − | − |
| 17 | M1 | 29 | PB | No | del (9) | + | − |
| 18 | M4 | 17 | PB | No | inv (16) | − | + |
| 19 | M5 | 13 | BM | No | N | + | ND |
AML cells derived from bone marrow (BM) or peripheral blood (PB); Percentage of CD34+ (% CD34+) in the total AML mononuclear cell fraction; AML CD34+ cells cultured in long-term culture assay demonstrated an expansion (y/n); FAB, French-American-British classifications; FLT3-ITD (internal tandem duplication) was present (+) or absent (−) in the AML cells; ND, not determined; N, normal